Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie Sells 689 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $12,581.14. Following the completion of the sale, the chief operating officer now directly owns 336,136 shares of the company’s stock, valued at $6,137,843.36. The trade was a 0.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Fulgent Genetics Trading Up 1.0 %

NASDAQ:FLGT opened at $18.07 on Friday. Fulgent Genetics, Inc. has a 1 year low of $16.56 and a 1 year high of $30.68. The stock has a fifty day moving average price of $19.86 and a two-hundred day moving average price of $21.14.

Wall Street Analysts Forecast Growth

FLGT has been the subject of a number of recent research reports. StockNews.com cut Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday. Piper Sandler reduced their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, November 11th.

Institutional Trading of Fulgent Genetics

Several hedge funds and other institutional investors have recently made changes to their positions in FLGT. Asset Dedication LLC purchased a new stake in shares of Fulgent Genetics in the second quarter valued at $33,000. Point72 DIFC Ltd purchased a new position in Fulgent Genetics in the 3rd quarter valued at about $46,000. nVerses Capital LLC purchased a new position in Fulgent Genetics in the 2nd quarter valued at about $43,000. Signaturefd LLC boosted its stake in shares of Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Fulgent Genetics during the second quarter worth about $63,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.